03-0208-00

SMC^® Human PD-L1 High Sensitivity Immunoassay Kit

kit sufficient for 96 wells

• Sinónimos: PD-L1 ultra-sensitive immunoassay, PD-L1 immunoassay kit, Programmed cell death protein ligand 1 kit, PD-L1 kit, Single Molecule Counting, SMC, SMC^®, PD-L1, Human PD-L1, Hu PD-L1, checkpoint protein PD-L1, Immuno-oncology PD-L1, PD-L1 Single Molecule Counting kit
• Código UNSPSC: 12161503
• NACRES: NA.51

Propiedades

• descripción: 100 μL of 1:4 Serum or 1:8 Plasma diluted in Standard Diluent
• Nivel de calidad: 200
• reactividad de especies: human
• fabricante / nombre comercial: SMC^®
• assay range: intra-assay cv: ≤10%; (n=15); linearity: 85-110%; (Plasma); linearity: 91-129%; (Serum); recovery range: 108 -143%; (Serum); recovery range: 70-110%; (Plasma); sensitivity: 0.78 pg/mL; standard curve range: 0.39-400 pg/mL; inter-assay cv: ≤15%; (n=15)
• técnicas: single molecule counting: suitable
• entrada: serum; plasma (K2 EDTA)
• Condiciones de envío: wet ice
• temp. de almacenamiento: 2-8°C

Descripción

Descripción general

Programmed cell death protein ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) and B7-H1, is a type 1 membrane protein of 290 amino acids. It is found in a variety of cell types and binds programmed cell death protein (PD-1). It has been indicated as playing a role in autoimmune disease, allograft responses, pregnancy, and other disease states. When PD-L1 binds to PD-1, an inhibitory signal is transmitted that ultimately reduces the proliferation of antigen-specific T cells and reduces the rate of apoptosis in regulatory T-cells. By doing so, PD-L1 contributes to the immune evasion of cancer tissues by suppressing the adaptive immune system. Blocking this activity is thought to restore anti-tumor activity. High PD-L1 expression is correlated with poor prognosis with some cancer types. High levels of the soluble form are also associated with poor prognosis and advanced tumor progression. Multiple PD-L1 inhibiting monoclonal antibodies have been approved as cancer therapeutics.

Research Category: Cancer

Research Sub-Category: Immuno-Oncology

Especificidad

This assay was tested for cross-reactivity with PD-1. No cross-reactivity was detected with this analyte.

Aplicación

Used for ultrasensitivite quantification of Human PD-L1 in human serum and plasma.

Características y beneficios

This SMC^® kit features:

• Accurate and reproducible performance on the state-of-the-art SMCxPRO^® ultrasensitive immunoassay system.
• Compatiblity with automated liquid handling

Información legal

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Información de seguridad

• Pictogramas: GHS08,GHS07
• Palabra de señalización: Danger
• Frases de peligro: H302 + H312 + H332,H319,H360FD,H373,H412
• Consejos de prudencia: P273 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313
• Clasificaciones de peligro: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Repr. 1B - STOT RE 2 Inhalation
• Órganos de actuación: Respiratory Tract
• Código de clase de almacenamiento: 6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable